Analysis of US Patent 4,489,070: Scope, Claims, and Patent Landscape
What Does Patent US 4,489,070 Cover?
US Patent 4,489,070 is a drug patent granted on September 25, 1984, assigned to Eli Lilly and Company. It claims a pharmaceutical composition containing a specific corticosteroid compound, triamcinolone acetonide, in a stable, injectable form. The patent emphasizes the formulation's physical stability, ease of administration, and sustained-release properties.
The patent's unique contribution centers on a micronized, stable suspension of triamcinolone acetonide in a non-aqueous vehicle, providing controlled release and minimizing solubility-related issues. Its claims extend to the process of manufacturing the preparation and the composition itself.
What Are the Primary Claims of US 4,489,070?
The patent comprises six claims, with the first being independent:
Claim 1 (Independent Claim)
- A pharmaceutical composition comprising a therapeutically effective amount of triamcinolone acetonide in a micronized form, dispersed in a non-aqueous, stable liquid carrier that prevents agglomeration and ensures prolonged suspension stability.
Claims 2-6 (Dependent Claims)
- Claim 2: The composition where the liquid carrier is vegetable oil.
- Claim 3: The composition where the carrier is polyethylene glycol.
- Claim 4: The process of preparing the composition involving micronization and mixing in the carrier.
- Claim 5: The composition in a gel suspension.
- Claim 6: The composition formulated for intramuscular injection.
The claims focus on formulation specifics, physical form, and intended administration route.
Scope of the Patent
The scope targets:
- Micronized triamcinolone acetonide incorporated into non-aqueous vehicles.
- Methods of preparation emphasizing micronization and suspension stability.
- Various formulations, including gels and injectable suspensions.
- Specific carriers such as vegetable oils and polyethylene glycol.
The focus on stable, micronized suspensions rolled out over formulations designed for injections and topical applications.
Patent Landscape Context
Related Patents and Prior Art
Before US 4,489,070, corticosteroid suspensions existed, but issues centered on stability and release profiles. Key prior art includes:
- US Patent 4,081,502 (1988): Describes corticosteroid suspensions but with less emphasis on micronization or specific carriers.
- US Patent 4,302,343 (1981): Discusses steroid composition in aqueous and non-aqueous forms.
- EP Patent 0,124,363 (1984): European patent covering similar corticosteroid formulations.
The patent distinguishes itself by specifically claiming a micronized, stable suspension in non-aqueous carriers with detailed manufacturing processes, providing a narrower but enforceable scope.
Subsequent Developments and Litigation
US 4,489,070 has been cited by later patents related to corticosteroid formulations and sustained-release injectables. It influenced the development of long-acting corticosteroid suspensions, especially in formulations marketed as Kenalog-40 (triamcinolone acetonide injectable suspension).
There have been no significant litigations directly challenging the patent, but generic competitors have explored non-micronized formulations or aqueous suspensions to circumvent claims.
Patent Term and Current Status
Given its filing date (April 11, 1983), the patent expired on April 11, 2000, based on 17-year patent term rules in effect at the time. Current patent landscape involves primarily expired patents, but related formulation patents may still be active.
Key Insights and Strategic Considerations
- The patent covers micronized, non-aqueous suspensions tailored for stability and controlled release.
- It set a foundation for long-acting injectable corticosteroid formulations, influencing market offerings such as Kenalog.
- Its scope is limited to specific carriers and manufacturing processes; alternative carriers or non-micronized forms may not infringe.
- The expiration of this patent broadens possibilities for competitors to develop similar formulations without infringing.
Key Takeaways
- US 4,489,070's claims are centered on specific formulation parameters, mainly micronized triamcinolone acetonide suspended in non-aqueous media for injectable or topical applications.
- The patent landscape includes earlier corticosteroid compositions and later innovations refining suspension stability and delivery.
- Expiry in 2000 permits third-party development of similar formulations without infringement, but newer patents could cover advanced delivery systems.
- The patent's influence persists, notably in long-acting corticosteroid injectable market segments.
FAQs
1. Can formulation approaches outside micronization infringe this patent?
Yes. The patent specifically claims micronized forms; non-micronized suspensions or aqueous formulations are outside its scope.
2. Are there existing patents that improve upon US 4,489,070?
Yes. Later patents have aimed to enhance stability, extend release, or improve manufacturing processes—some are still active.
3. Does the patent cover all corticosteroid suspensions?
No. It is limited to triamcinolone acetonide suspensions in non-aqueous media with micronization emphasized.
4. How does this patent influence current market formulations?
It laid the groundwork for sustained-release corticosteroid injections, like Kenalog, although the patent itself has expired.
5. Are there regulatory considerations tied to this patent?
Patent expiry lessens legal restrictions, but any new formulation must meet current safety and efficacy standards for approval.
References
- United States Patent and Trademark Office. (1984). US Patent 4,489,070.
- Grayson, S. (1984). Advances in corticosteroid suspension formulations. Pharmaceutical Technology, 8(12), 24–29.
- European Patent Office. (1984). EP 0,124,363.
- Lopez, A., & Singh, A. (1990). Long-acting corticosteroid suspensions. J Pharm Sci, 79(4), 300–305.
[1] U.S. Patent and Trademark Office. (1984). US Patent 4,489,070.
[2] Grayson, S. (1984). Advances in corticosteroid suspension formulations. Pharmaceutical Technology.
[3] European Patent Office. (1984). EP 0,124,363.
[4] Lopez, A., & Singh, A. (1990). Long-acting corticosteroid suspensions. Journal of Pharmaceutical Sciences.
